Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: A Japan Clinical Oncology Group trial (JCOG 0102)

British Journal of Cancer

Volumn 108, Issue 10, 2013, Pages 1957-1963

  Katsumata, N ^a   Yoshikawa, H ^b   Kobayashi, H ^c   Saito, T ^d   Kuzuya, K ^e   Nakanishi, T ^f   Yasugi, T ^g   Yaegashi, N ^h   Yokota, H ⁱ   Kodama, S ^j   Mizunoe, T ^k   Hiura, M ^l   Kasamatsu, T ^m   Shibata, T ⁿ   Kamura, T ^o  

^a NIPPON MEDICAL SCHOOL MUSASHI KOSUGI HOSPITAL   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d NATIONAL KYUSHU CANCER CENTER   (Japan)

^e Kuzuya Clinic   (Japan)

^f AICHI CANCER CENTER HOSPITAL   (Japan)

^g UNIVERSITY OF TOKYO   (Japan)

^h TOHOKU UNIVERSITY   (Japan)

ⁱ SAITAMA CANCER CENTER   (Japan)

^j Niigata Cancer Center   (Japan)

^k National Hospital Organization   (Japan)

^l NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^m NATIONAL CANCER CENTER HOSPITAL   (Japan)

ⁿ NATIONAL CANCER CENTER   (Japan)

^o KURUME UNIVERSITY   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; MITOMYCIN; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ALKALOSIS; ARTICLE; BLADDER INJURY; BLEEDING; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CYSTOVAGINAL FISTULA; DIARRHEA; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG WITHDRAWAL; DYSURIA; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; INTESTINE OBSTRUCTION; JAPAN; LYMPH NODE METASTASIS; LYMPHEDEMA; MULTIPLE CYCLE TREATMENT; NAUSEA; OPERATION DURATION; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; POSTOPERATIVE CARE; PRIORITY JOURNAL; RADICAL HYSTERECTOMY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SKIN TOXICITY; SKIN ULCER; SURGICAL INFECTION; THROMBOCYTOPENIA; THROMBOSIS; URETER INJURY; URINE RETENTION; UTERINE CERVIX CARCINOMA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; BRACHYTHERAPY; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; HYSTERECTOMY; JAPAN; MEDICAL ONCOLOGY; MIDDLE AGED; MITOMYCIN; NEOADJUVANT THERAPY; NEOPLASM STAGING; UTERINE CERVICAL NEOPLASMS; VINCRISTINE; YOUNG ADULT;

EID: 84878524481     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.179     Document Type: Article

References (26)

1. Buda A, Fossati R, Colombo N, Fei F, Floriani I, Gueli Alletti D, Katsaros D, Landoni F, Lissoni A, Malzoni C, Sartori E, Scollo P, Torri V, Zola P, Mangioni C (2005) Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study. J Clin Oncol 23(18): 4137-4145.
2. Cai HB, Chen HZ, Yin HH (2006) Randomized study of preoperative chemotherapy versus primary surgery for stage IB cervical cancer. J Obstet Gynaecol Res 32(3): 315-323.
3. Chen H, Liang C, Zhang L, Huang S, Wu X (2008) Clinical efficacy of modified preoperative neoadjuvant chemotherapy in the treatment of locally advanced (stage IB2 to IIB) cervical cancer: randomized study. Gynecol Oncol 110(3): 308-315.
4. Eddy GL, Bundy BN, Creasman WT, Spirtos NM, Mannel RS, Hannigan E, O'Connor D (2007) Treatment of (''bulky'') stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: a phase III trial of the gynecologic oncology group. Gynecol Oncol 106(2): 362-369.
5. EORTC 55994. http://www.cancer.gov/clinicaltrials/search/view?cdrid= 69375&version=healthprofessional
6. Fujii S, Takakura K, Matsumura N, Higuchi T, Yura S, Mandai M, Baba T, Yoshioka S (2007) Anatomic identification and functional outcomes of the nerve sparing Okabayashi radical hysterectomy. Gynecol Oncol 107(1): 4-13.
7. Green S, Benedetti J, Crowley J (1997) Interim Analysis and Data Monitoring Committee. Clinical Trials in Oncology, 1st edn, pp 80-99. Chapman & Hall/CRC.
8. Katsumata N, Yoshikawa H, Hirakawa T, Saito T, Kuzuya K, Fujii T, Hiura M, Tsunematsu R, Fukuda H, Kamura T (2006) Phase III randomized trial of neoadjuvant chemotherapy (NAC) followed by radical hysterectomy (RH) versus RH for bulky stage I/II cervical cancer (JCOG 0102). Proc Am Soc Clin Oncol 24((No 18S)): abstract 5013.
9. Long 3rd HJ, Bundy BN, Grendys Jr EC, Benda JA, McMeekin DS, Sorosky J, Miller DS, Eaton LA, Fiorica JV (2005) Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 23(21): 4626-4633.
10. Matsumura M, Takeshima N, Ota T, Omatsu K, Sakamoto K, Kawamata Y, Umayahara K, Tanaka H, Akiyama F, Takizawa K (2010) Neoadjuvant chemotherapy followed by radical hysterectomy plus postoperative chemotherapy but no radiotherapy for Stage IB2-IIB cervical cancer-irinotecan and platinum chemotherapy. Gynecol Oncol 119(2): 212-216.
11. Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, Miller DS, Olt G, King S, Boggess JF, Rocereto TF (2004) Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 22(15): 3113-3119.
12. Napolitano U, Imperato F, Mossa B, Framarino ML, Marziani R, Marzetti L (2003) The role of neoadjuvant chemotherapy for squamous cell cervical cancer (Ib-IIIb): a long-term randomized trial. Eur J Gynaecol Oncol 24(1): 51-59.
13. NCCN Clinical Practice Guidelines (2012) Oncology-Cervical Cancer, version I. National Comprehensive Cancer Network. http://www.nccn.org/ professionals/physician-gls/pdf/cervical.pdf. NCT00193739. http:// clinicaltrials.gov/ct2/show/NCT00193739?term=NCT00193739.
14. Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Metaanalysis Collaboration (2003) Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials. Eur J Cancer 39(17): 2470-2486.
15. Okabayashi H (1921) Radical abdominal hysterectomy for cancer of the cervixuteri, modification of the Takayama operation. Surg Gynecol Obstet 33: 335-341.
16. Omura GA, Blessing JA, Vaccarello L, Berman ML, Clarke-Pearson DL, Mutch DG, Anderson B (1997) Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 15(1): 165-171.
17. Pecorelli S, Zigliani L, Odicino F (2009) Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet 105(2): 107-108.
18. Peters 3rd WA, Liu PY, Barrett 2nd RJ, Stock RJ, Monk BJ, Berek JS, Souhami L, Grigsby P, Gordon Jr W, Alberts DS (2000) Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in highrisk early-stage cancer of the cervix. J Clin Oncol 18(8): 1606-1613.
19. Piver MS, Rutledge F, Smith JP (1974) Five classes of extended hysterectomy for women with cervical cancer. Obstet Gynecol 44(2): 265-272.
20. Rydzewska L, Tierney J, Vale CL, Symonds PR (2010) Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. Cochrane Database Syst Rev (1): CD007406.
21. Sardi JE, Giaroli A, Sananes C, Ferreira M, Soderini A, Bermudez A, Snaidas L, Vighi S, Gomez Rueda N, di Paola G (1997) Long-term follow-up of the first randomized trial using neoadjuvant chemotherapy in stage Ib squamous carcinoma of the cervix: the final results. Gynecol Oncol 67(1): 61-69.
22. Schoenfeld DA, Richter JR (1982) Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. Biometrics 38(1): 163-170.
23. Shimizu Y, Akiyama F, Umezawa S, Ishiya T, Utsugi K, Hasumi K (1998) Combination of consecutive low-dose cisplatin with bleomycin, vincristine, and mitomycin for recurrent cervical carcinoma. J Clin Oncol 16(5): 1869-1878.
24. Spiegelhalter DJ, Freedman LS, Parmar MK (1993) Applying Bayesian ideas in drug development and clinical trials. Stat Med 12(15-16): 1501-1511 discussion 1513-7.
25. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3): 205-216.
26. Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, Gunderson L, McCormick B, Morrisintegral M, Rich T, Shipley W, Curran W (2000) Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 47(1): 13-47.